[go: up one dir, main page]

MXPA05012810A - Formas de dosis oral de memantina. - Google Patents

Formas de dosis oral de memantina.

Info

Publication number
MXPA05012810A
MXPA05012810A MXPA05012810A MXPA05012810A MXPA05012810A MX PA05012810 A MXPA05012810 A MX PA05012810A MX PA05012810 A MXPA05012810 A MX PA05012810A MX PA05012810 A MXPA05012810 A MX PA05012810A MX PA05012810 A MXPA05012810 A MX PA05012810A
Authority
MX
Mexico
Prior art keywords
memantine
dosage form
dosage forms
oral dosage
memantine oral
Prior art date
Application number
MXPA05012810A
Other languages
English (en)
Inventor
J Abraham M Espiritu
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MXPA05012810A publication Critical patent/MXPA05012810A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invencion se refiere a una forma de dosis oral que contiene entre 1 mg y 100 mg de memantina, en donde la forma de dosis no contiene 10 mg de memantina o 20 mg de memantina, y en donde la forma de dosis no es preparada por el paciente o una persona que administra el farmaco al paciente, quien divide la forma de dosis que contiene una dosis mas grande de memantina. Otros aspectos de esta invencion se refieren a los productos farmaceuticos que comprenden formas de dosis y metodos de administrar la memantina, y tratar la enfermedad con la forma de dosis.
MXPA05012810A 2003-06-16 2004-06-10 Formas de dosis oral de memantina. MXPA05012810A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47897903P 2003-06-16 2003-06-16
PCT/US2004/018506 WO2004112768A1 (en) 2003-06-16 2004-06-10 Memantine oral dosage forms

Publications (1)

Publication Number Publication Date
MXPA05012810A true MXPA05012810A (es) 2006-02-13

Family

ID=33539133

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012810A MXPA05012810A (es) 2003-06-16 2004-06-10 Formas de dosis oral de memantina.

Country Status (16)

Country Link
US (2) US20040254251A1 (es)
EP (1) EP1631273A1 (es)
JP (1) JP2006527774A (es)
KR (1) KR20060033727A (es)
CN (1) CN1805737A (es)
AU (1) AU2004249151A1 (es)
BR (1) BRPI0411451A (es)
CA (1) CA2529535A1 (es)
IL (1) IL172233A0 (es)
MX (1) MXPA05012810A (es)
NO (1) NO20055880L (es)
PL (1) PL378902A1 (es)
RU (1) RU2006101225A (es)
TW (1) TW200524639A (es)
WO (1) WO2004112768A1 (es)
ZA (1) ZA200509379B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
FR2855344A1 (fr) * 2003-05-22 2004-11-26 France Telecom Systeme de gestion de contexte pour un reseau comportant un ensemble heterogene de terminaux
JP5025468B2 (ja) * 2004-06-17 2012-09-12 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
RU2404750C2 (ru) * 2004-11-23 2010-11-27 Адамас Фармасьютикалс, Инк. Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
CA2592605C (en) 2004-12-27 2010-12-07 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
AU2006241771B2 (en) * 2005-04-28 2010-09-09 Eisai R & D Management Co., Ltd. Composition containing anti-dementia drug
CN101415690A (zh) * 2006-02-10 2009-04-22 詹森药业有限公司 作为钾通道开放剂的新的三环二氢吡嗪化合物
AU2007241809A1 (en) * 2006-04-20 2007-11-01 Itoham Foods Inc. Pharmaceutical composition for conformational disease
WO2008005036A1 (en) * 2006-07-05 2008-01-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of memantine
EP1908748A1 (en) * 2006-10-05 2008-04-09 Krka Process for the preparation of memantine and its hydrochloric acid salt form
JP2010507672A (ja) * 2006-10-27 2010-03-11 メディベイション ニューロロジー， インコーポレイテッド アルツハイマー病を治療するための方法および組み合わせ治療
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
EP2170310A4 (en) * 2007-06-29 2010-06-23 Orchid Chemicals & Pharm Ltd FAST-DISSOLVING COMPOSITIONS OF MEMANTINE HYDROCHLORIDE
EP2583669A1 (en) 2007-10-10 2013-04-24 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009091932A2 (en) * 2008-01-18 2009-07-23 Adamas Pharmaceuticals, Inc. Treatment of mild dementia of the alzheimer's disease type
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
BR112014026292B1 (pt) * 2012-04-24 2022-09-27 Daiichi Sankyo Company, Limited Comprimido oralmente desintegrável, e, processo para a produção de um comprimido oralmente desintegrável
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
KR20190076711A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 메만틴을 포함하는 속방성 및 서방성을 동시에 가지는 경질캡슐 제제 및 그 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods

Also Published As

Publication number Publication date
KR20060033727A (ko) 2006-04-19
JP2006527774A (ja) 2006-12-07
WO2004112768A1 (en) 2004-12-29
TW200524639A (en) 2005-08-01
AU2004249151A1 (en) 2004-12-29
EP1631273A1 (en) 2006-03-08
RU2006101225A (ru) 2006-06-10
US20040254251A1 (en) 2004-12-16
ZA200509379B (en) 2006-11-29
IL172233A0 (en) 2006-04-10
US20060251717A1 (en) 2006-11-09
CN1805737A (zh) 2006-07-19
CA2529535A1 (en) 2004-12-29
PL378902A1 (pl) 2006-05-29
NO20055880L (no) 2005-12-28
BRPI0411451A (pt) 2006-07-18

Similar Documents

Publication Publication Date Title
MXPA05012810A (es) Formas de dosis oral de memantina.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
EA200401317A1 (ru) Композиции и способы дозирования липосом определенных размеров для лечения или предотвращения заболевания
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
EP1001772A4 (en) IMPROVEMENTS IN THE ADMINISTRATION OF MULTIPLE DRUG DOSAGES
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
RU2008122358A (ru) Лекарственные формы, содержащие ag013736
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
MXPA04001912A (es) Aminobenzofenonas novedosas.
RU2002124141A (ru) Применение миртазапина для лечения расстройств сна
KR960028907A (ko) 암환자를 치료하기 위한 세트랄린의 용도
EA200800075A1 (ru) Схема дозирования для празугреля
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására

Legal Events

Date Code Title Description
FA Abandonment or withdrawal